Feeds
10095 items (10095 unread) in 74 feeds
Acinar Cell Carcinoma
(96 unread)
Acinic Cell Carcinoma
(21 unread)
Adenoid Cystic Carcinoma
(223 unread)
Adrenal Gland Cancer
(899 unread)
Ampulla Of Vater
(75 unread)
Anal Cancer
(911 unread)
Angiosarcoma
(174 unread)
Appendix Cancer
(147 unread)
Bile Duct Cancer
(1427 unread)
Brain and CNS
(1389 unread)
Carcinoid
(311 unread)
Endocrine/Neuroendocrine
(968 unread)
Gall Bladder Cancer
(431 unread)
Hemangioendothelioma
(248 unread)
Hepatoblastoma
(123 unread)
Pancreas
(139 unread)
Phyllodes
(95 unread)
PMP and Mucinous Tumors
(62 unread)
Rhabdomyosarcoma
(337 unread)
Sarcoma
(2019 unread)
Unread items (100)
Google - Acinar Cell Carcinoma
-
Prognostic significance of microscopic size in peripherally located scar-associated clinical stage I lung carcinomas. - Physician's Weekly
Posted: March 23rd, 2020, 3:06pm GMT
-
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial - The Lancet
Posted: March 2nd, 2020, 9:40pm GMT
-
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial - The Lancet
Posted: March 2nd, 2020, 9:32pm GMT
-
Recent insights into the biology of pancreatic cancer - The Lancet
Posted: March 2nd, 2020, 6:00am GMT
-
More time between prostate cancer screenings could improve outcomes - Medical Xpress
Posted: February 19th, 2020, 6:25am GMT
-
Statins may lower mortality in high-risk prostate cancer patients - Medical Xpress
Posted: February 10th, 2020, 2:25pm GMT
-
Similar survival of African-American and white men with prostate cancer in an equal-access health care system - Medical Xpress
Posted: January 27th, 2020, 6:25am GMT
-
Poly(vinyl alcohol) boosting therapeutic potential of p-boronophenylalanine in neutron capture therapy by modulating metabolism - Science Advances
Posted: January 22nd, 2020, 6:00am GMT
-
Hormone therapy now available for newly diagnosed prostate cancer in Scotland - Medical Xpress
Posted: January 21st, 2020, 11:25am GMT
-
Cheap roundworm drug found to enhance the effects of chemotherapy in prostate cancer - Medical Xpress
Posted: January 17th, 2020, 1:05pm GMT
-
Unfruitful: Eating more produce will not cure, stop prostate cancer - Medical Xpress
Posted: January 14th, 2020, 3:25pm GMT
-
Prostate cancer can now be diagnosed better using artificial intelligence - Medical Xpress
Posted: January 9th, 2020, 6:00am GMT
-
AI can be used to detect and grade prostate cancer - Medical Xpress
Posted: January 8th, 2020, 9:34pm GMT
AI can be used to detect and grade prostate cancer Medical Xpress -
Targeted screening could prevent one in six prostate cancer deaths - Medical Xpress
Posted: December 20th, 2019, 5:04pm GMT
-
PET/CT plays role in lung adenocarcinoma management - Medical Xpress
Posted: December 16th, 2019, 6:00am GMT
PET/CT plays role in lung adenocarcinoma management Medical Xpress -
Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer - Medical Xpress
Posted: December 3rd, 2019, 6:00am GMT
-
High-fat diet proven to fuel prostate cancer progression by imitating a key cancer alteration - Medical Xpress
Posted: November 29th, 2019, 10:58am GMT
-
Prostate cancer 'super responders' live for two years on immunotherapy - Medical Xpress
Posted: November 27th, 2019, 6:00am GMT
-
Prostate cancer bone metastases thwart immunotherapy by producing TGF-beta - Medical Xpress
Posted: November 14th, 2019, 2:08pm GMT
-
High levels of two hormones in the blood raise prostate cancer risk - Medical Xpress
Posted: November 1st, 2019, 5:00am GMT
-
First prostate cancer therapy to target genes delays cancer progression - Medical Xpress
Posted: September 30th, 2019, 1:36pm GMT
-
Study finds potential therapeutic target for prostate cancers with PTEN mutation - Medical Xpress
Posted: September 24th, 2019, 12:13pm GMT
-
Scientists identify new family of drugs which could combat prostate cancer - Medical Xpress
Posted: September 20th, 2019, 2:25pm GMT
-
New blood test for prostate cancer is highly-accurate and avoids invasive biopsies - Medical Xpress
Posted: September 10th, 2019, 2:40pm GMT
-
Eating mushrooms may help lower prostate cancer risk - Medical Xpress
Posted: September 5th, 2019, 5:00am GMT
Eating mushrooms may help lower prostate cancer risk Medical Xpress -
New prostate cancer treatment concept - Medical Xpress
Posted: August 26th, 2019, 5:00am GMT
New prostate cancer treatment concept Medical Xpress -
Pancreatic cancer clue - Medical Xpress
Posted: August 19th, 2019, 5:00am GMT
Pancreatic cancer clue Medical Xpress -
Adjuvant radiotherapy may be beneficial in treating locally advanced prostate cancer - Medical Xpress
Posted: July 30th, 2019, 5:00am GMT
-
Prostate cancer treatment linked to dementia risk - Medical Xpress
Posted: July 8th, 2019, 5:00am GMT
Prostate cancer treatment linked to dementia risk Medical Xpress -
Dementia tied to hormone-blocking prostate cancer treatment - Medical Xpress
Posted: July 5th, 2019, 4:41pm GMT
Dementia tied to hormone-blocking prostate cancer treatment Medical Xpress -
Noninvasive test improves detection of aggressive prostate cancer - Medical Xpress
Posted: July 1st, 2019, 6:00pm GMT
-
Prostate cancer urine test shows who needs treatment and when - Medical Xpress
Posted: June 26th, 2019, 5:00am GMT
-
Body fat distribution linked to higher risk of aggressive prostate cancer - Medical Xpress
Posted: June 10th, 2019, 5:40am GMT
-
ARID1A spatially partitions interphase chromosomes - Science Advances
Posted: May 22nd, 2019, 5:00am GMT
ARID1A spatially partitions interphase chromosomes Science Advances -
A new method to select the right treatment for advanced prostate cancer - Medical Xpress
Posted: May 3rd, 2019, 9:35am GMT
-
Removal of gene prevents development of pancreatic cancer in mice - Medical Xpress
Posted: May 2nd, 2019, 5:00am GMT
-
Single dose of targeted radiotherapy is safe and effective for prostate cancer - Medical Xpress
Posted: April 29th, 2019, 5:00am GMT
-
Prostate cancer hormone therapy rejected on NHS in England - Medical Xpress
Posted: April 8th, 2019, 5:00am GMT
Prostate cancer hormone therapy rejected on NHS in England Medical Xpress -
Scientists identify compounds in coffee which may inhibit prostate cancer - Medical Xpress
Posted: March 18th, 2019, 5:00am GMT
-
Testosterone slows prostate cancer recurrence in low-risk patients - Medical Xpress
Posted: March 17th, 2019, 5:00am GMT
-
How prostate cancer becomes treatment resistant - Medical Xpress
Posted: February 28th, 2019, 2:00pm GMT
How prostate cancer becomes treatment resistant Medical Xpress -
Immunotherapy combination generates responses against castration-resistant metastatic prostate cancer - Medical Xpress
Posted: February 15th, 2019, 6:00am GMT
-
Prostate cancer study shows promise for future treatment - Medical Xpress
Posted: February 4th, 2019, 6:00am GMT
Prostate cancer study shows promise for future treatment Medical Xpress -
Inadequate support for sexual dysfunction in prostate cancer patients - Medical Xpress
Posted: February 4th, 2019, 6:00am GMT
-
Surgery unnecessary for many prostate cancer patients - Medical Xpress
Posted: December 13th, 2018, 11:05am GMT
Surgery unnecessary for many prostate cancer patients Medical Xpress -
Which Approach is Best for Biopsy Gleason Score 9–10 Prostate Cancer? - Cancer Network
Posted: December 11th, 2018, 6:00am GMT
-
Inflammatory bowel disease linked to prostate cancer - Medical Xpress
Posted: December 7th, 2018, 4:33pm GMT
Inflammatory bowel disease linked to prostate cancer Medical Xpress -
Revolutionary technology pinpoints biopsies to detect prostate cancer - Medical Xpress
Posted: December 5th, 2018, 6:00am GMT
-
Best Agents Should Be Used Upfront for the Treatment of NSCLC, Levy Says - Targeted Oncology
Posted: December 4th, 2018, 6:00am GMT
Best Agents Should Be Used Upfront for the Treatment of NSCLC, Levy Says Targeted Oncology -
Pancreatic cancer: Symptoms, causes, and treatment - Medical News Today
Posted: October 26th, 2018, 5:00am GMT
Pancreatic cancer: Symptoms, causes, and treatment Medical News Today -
ALS drug may help treat prostate cancer - Medical Xpress
Posted: October 3rd, 2018, 5:00am GMT
ALS drug may help treat prostate cancer Medical Xpress -
Combo therapy of prostatectomy plus radiotherapy may improve survival in prostate cancer - Medical Xpress
Posted: September 25th, 2018, 1:31pm GMT
-
Experts advise against routine testing for prostate cancer - Medical Xpress
Posted: September 5th, 2018, 8:49pm GMT
Experts advise against routine testing for prostate cancer Medical Xpress -
Hormone therapy can make prostate cancer worse, study finds - Medical Xpress
Posted: September 5th, 2018, 5:56am GMT
Hormone therapy can make prostate cancer worse, study finds Medical Xpress -
Immunotherapy drug for skin disease could boost hormone treatment for prostate cancer - Medical Xpress
Posted: June 27th, 2018, 5:00am GMT
-
Pancreatic cell size linked to mammalian lifespan, finds zoo animal analysis - Phys.org
Posted: June 18th, 2018, 2:06pm GMT
-
DVM 360 - dvm360
Posted: June 7th, 2018, 5:00am GMT
DVM 360 dvm360 -
Bone scan software accurately calculates prognosis of advanced prostate cancer - Medical Xpress
Posted: May 17th, 2018, 5:00am GMT
-
Initiation of ADT in a Man With Locally Advanced Prostate Cancer and Multiple Cardiovascular Risk Factors - Cancer Network
Posted: May 15th, 2018, 5:00am GMT
-
Injecting gene cocktail into mouse pancreas leads to humanlike tumors - Medical Xpress
Posted: April 5th, 2018, 5:00am GMT
-
Multiple-treatment approach improves survival rates in aggressive prostate cancer, study finds - Medical Xpress
Posted: March 7th, 2018, 6:00am GMT
-
Publications - Microscopy - Shared Resources - UC San Diego Moores Cancer Center - UC San Diego Health
Posted: January 15th, 2018, 6:40pm GMT
Publications - Microscopy - Shared Resources - UC San Diego Moores Cancer Center UC San Diego Health -
Specific protein promotes development of pancreatitis and tumours - Medical Xpress
Posted: December 5th, 2017, 6:00am GMT
-
Cell death linked to tumor growth in prostate cancer patients - Medical Xpress
Posted: November 27th, 2017, 7:10pm GMT
-
Low testosterone levels linked to reduced risk of prostate cancer - Medical Xpress
Posted: November 6th, 2017, 6:00am GMT
-
Androgen deprivation therapy increases risk of heart failure in men with prostate cancer - Medical Xpress
Posted: August 24th, 2017, 5:00am GMT
-
Treatment extends life for some with advanced prostate cancer - Medical Xpress
Posted: June 3rd, 2017, 8:10pm GMT
-
New targeted molecular therapy takes aim at incurable prostate cancer - Medical Xpress
Posted: May 31st, 2017, 5:00am GMT
-
New test distinguishes 'tigers' from 'pussycats' in prostate cancer - Medical Xpress
Posted: March 1st, 2017, 10:10pm GMT
-
Research team identifies role for a microRNA involved in prostate cancer metastasis - Medical Xpress
Posted: January 25th, 2017, 10:11am GMT
-
Rebuilding the salivary gland after radiation - Medical Xpress
Posted: January 12th, 2017, 6:00am GMT
Rebuilding the salivary gland after radiation Medical Xpress -
Role of protein in pancreatic secretion suggests potential method for treating diabetes - Medical Xpress
Posted: December 8th, 2016, 6:00am GMT
-
Pricey new treatment raises questions about how to treat prostate cancer - Medical Xpress
Posted: October 10th, 2016, 5:00am GMT
-
One single biopsy not sufficient to guide treatment decisions in prostate cancer - Medical Xpress
Posted: September 22nd, 2016, 5:00am GMT
-
International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #25: Insulin Gene Expression and Biosynthesis Part 1 of 6 - Diabetes In Control
Posted: May 24th, 2016, 5:00am GMT
-
Heat-shock factor 2 is a suppressor of prostate cancer invasion - Nature.com
Posted: June 29th, 2015, 5:00am GMT
-
Pancreatic cancer breakthrough: Scientists turn cancer cells into normal cells - Medical Xpress
Posted: April 20th, 2015, 5:00am GMT
-
Diagnosing prostate cancer could be as easy as peeing on a stick - Medical Xpress
Posted: October 31st, 2014, 5:00am GMT
-
New prostate cancer screening guideline recommends not using PSA test - Medical Xpress
Posted: October 27th, 2014, 5:00am GMT
-
Cellular alchemy: How to make insulin-producing cells from gut cells - Medical Xpress
Posted: March 11th, 2014, 5:00am GMT
-
How To Enhance Non-thermal Effects Of Ultrasound - Science Daily (press release)
Posted: December 29th, 2008, 6:00am GMT
How To Enhance Non-thermal Effects Of Ultrasound Science Daily (press release) -
Promising Chinese Herbal Targets Identified For Acute Pancreatitis - Science Daily (press release)
Posted: June 21st, 2008, 5:00am GMT
Promising Chinese Herbal Targets Identified For Acute Pancreatitis Science Daily (press release)
PubMed - Acinar Cell Carcinoma
-
Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study.
Fetched: March 29th, 2020, 5:00am GMT
Related Articles Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study.
Clin Genitourin Cancer. 2019 06;17(3):231-237.e2
Authors: Knipper S, Preisser F, Mazzone E, Mistretta FA, Tian Z, Briganti A, Zorn KC, Saad F, Tilki D, Graefen M, Karakiewicz PI
Abstract
PURPOSE: To investigate clinicopathologic characteristics and cancer-specific mortality (CSM) rates of ductal carcinoma (DC) versus the common acinar adenocarcinoma in nonmetastatic and metastatic (M1) prostate cancer patients.
PATIENTS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2015), we identified patients with histologically confirmed prostate adenocarcinoma who harbored either DC (n = 581) or acinar adenocarcinoma (n = 489,296). Kaplan-Meier and 4:1 propensity score-matched multivariable Cox regression models adjusted for clinical and pathologic parameters were used to test for CSM differences. Three separate analyses were performed on all patients with nonmetastatic disease, patients with nonmetastatic patients treated with radical prostatectomy only, and patients with metastatic disease.
RESULTS: DC was identified in 502 (0.10%) of 469,946 patients with nonmetastatic disease and 79 (0.39%) of 19,931 patients with metastatic disease. In patients with nonmetastatic disease, 253 (50.4%) DC patients underwent radical prostatectomy, 61 (12.2%) DC patients received external-beam radiotherapy, and 188 (37.4%) received other treatment modalities. In multivariable analyses, DC was associated with higher CSM in the overall nonmetastatic patient population (hazard ratio [HR] = 1.8; 95% confidence interval [CI], 1.3-2.6; P = .001), in the nonmetastatic radical prostatectomy population (HR = 2.8; 95% CI, 1.3-6.0; P < .01), and in the M1 population (HR = 1.6; 95% CI, 1.1-2.2; P < .01).
CONCLUSION: Prostate cancers of ductal origin represent a rare entity among patients with nonmetastatic disease as well as among patients with metastatic disease, and regardless of stage, DC behaves more aggressively.
PMID: 31080021 [PubMed - indexed for MEDLINE]
-
Metabolism and epigenetics of pancreatic cancer stem cells.
Fetched: March 29th, 2020, 5:00am GMT
Related Articles Metabolism and epigenetics of pancreatic cancer stem cells.
Semin Cancer Biol. 2019 08;57:19-26
Authors: Perusina Lanfranca M, Thompson JK, Bednar F, Halbrook C, Lyssiotis C, Levi B, Frankel TL
Abstract
Pancreatic Cancer (PDA) is an aggressive malignancy characterized by early spread and a high mortality. Current studies suggest that a subpopulation of cells exist within tumors, cancer stem cell (CSC), which are capable of self-renewal and give rise to unique progeny which form the major neoplastic cellular component of tumors. While CSCs constitute a small cellular subpopulation within the tumor, their resistance to chemotherapy and radiation make them an important therapeutic target for eradication. Along with distinctive phenotypic properties, CSCs possess a unique metabolic plasticity allowing them to rapidly respond and adapt to environmental changes. These cells and their progeny also display a significantly altered epigenetic state with distinctive patterns of DNA methylation. Several mechanisms of cross-talk between epigenetic and metabolic pathways in PDA exist which ultimately contribute to the observed cellular plasticity and enhanced tumorigenesis. In this review we discuss various examples of this metabolic-epigenetic interplay and how it may constitute a new avenue for therapy specifically targeting CSCs in PDA.
PMID: 30273655 [PubMed - indexed for MEDLINE]
-
Prognostic significance of microscopic size in peripherally located scar-associated clinical stage I lung carcinomas.
Fetched: March 24th, 2020, 5:00am GMT
Related Articles Prognostic significance of microscopic size in peripherally located scar-associated clinical stage I lung carcinomas.
Lung Cancer. 2020 Mar 07;143:12-18
Authors: Trejo Bittar HE, Jerome JA, Hartman D, Pantanowitz L, Mehrad M, Dacic S
Abstract
OBJECTIVES: Staging of non-small cell lung carcinoma associated with scar is not discussed in detail in the current American Joint Committee on Cancer staging manual. The recommendation is to include the scar area in the tumor size measurement unless the tumor represents a small focus at the edge of the scar. The aim of this study is to investigate if subtraction of the size of the central scar from the total gross size of surgically resected peripheral clinical stage I non-small cell lung carcinoma improves patient stratification into more accurate prognostic groups.
MATERIALS AND METHODS: Hematoxylin and eosin sections of 148 non-small cell lung carcinomas (98 adenocarcinomas and 50 squamous cell carcinomas) were reviewed, including 44 adenocarcinomas and 9 squamous cell carcinomas with scar and 54 adenocarcinomas and 41 squamous cell carcinomas without scar. The microscopic size of the invasive tumor component was determined after the average percentage of scar tissue was subtracted from the grossly measured tumor diameter. Manual results were compared to digital image analysis.
RESULTS: Adenocarcinoma with scar were associated with better overall (80.5 % vs. 63.2 %, p = 0.026) and cancer specific survival (95.2 % vs. 73.3 %, p = 0.0053) when compared to adenocarcinoma without scar. Better cancer specific survival was observed in acinar and papillary predominant adenocarcinoma (95.8 % with scar vs. 67.8 % without scar, p = 0.01); while similar trend although not statistically significant was observed in adenocarcinomas with solid or micropapillary component. Using microscopic size, pathologic T stage was down-staged in 21 adenocarcinomas. Squamous cell carcinoma with or without scar did not show a difference in survival. Manual and quantitative image analysis showed strong correlation (r = 0.9769, p < 0.0001).
CONCLUSION: Our study suggests that microscopic size of the invasive component in acinar and papillary predominant adenocarcinoma with scar might be a better predictor of survival than the total gross size.
PMID: 32200136 [PubMed - as supplied by publisher]
-
PRDM3 attenuates pancreatitis and pancreatic tumorigenesis by regulating inflammatory response.
Fetched: March 19th, 2020, 5:00am GMT
Related Articles PRDM3 attenuates pancreatitis and pancreatic tumorigenesis by regulating inflammatory response.
Cell Death Dis. 2020 Mar 16;11(3):187
Authors: Ye J, Huang A, Wang H, Zhang AMY, Huang X, Lan Q, Sato T, Goyama S, Kurokawa M, Deng C, Sander M, Schaeffer DF, Li W, Kopp JL, Xie R
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is associated with metaplastic changes in the pancreas but the transcriptional program underlying these changes is incompletely understood. The zinc finger transcription factor, PRDM3, is lowly expressed in normal pancreatic acini and its expression increases during tumorigenesis. Although PRDM3 promotes proliferation and migration of PDAC cell lines, the role of PRDM3 during tumor initiation from pancreatic acinar cells in vivo is unclear. In this study, we showed that high levels of PRDM3 expression in human pancreas was associated with pancreatitis, and well-differentiated but not poorly differentiated carcinoma. We examined PRDM3 function in pancreatic acinar cells during tumor formation and pancreatitis by inactivating Prdm3 using a conditional allele (Ptf1aCreER;Prdm3flox/flox mice) in the context of oncogenic Kras expression and supraphysiological cerulein injections, respectively. In Prdm3-deficient mice, KrasG12D-driven preneoplastic lesions were more abundant and progressed to high-grade precancerous lesions more rapidly. This is consistent with our observations that low levels of PRDM3 in human PDAC was correlated significantly with poorer survival in patient. Moreover, loss of Prdm3 in acinar cells elevated exocrine injury, enhanced immune cell activation and infiltration, and greatly increased acinar-to-ductal cell reprogramming upon cerulein-induced pancreatitis. Whole transcriptome analyses of Prdm3 knockout acini revealed that pathways involved in inflammatory response and Hif-1 signaling were significantly upregulated in Prdm3-depleted acinar cells. Taken together, our results suggest that Prdm3 favors the maintenance of acinar cell homeostasis through modulation of their response to inflammation and oncogenic Kras activation, and thus plays a previously unexpected suppressive role during PDAC initiation.
PMID: 32179733 [PubMed - in process]
-
Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context".
Fetched: March 16th, 2020, 5:00am GMT
Related Articles Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context".
Curr Probl Cancer. 2020 Feb 28;:100561
Authors: Nakra T, Mehta A, Bal A, Nambirajan A, Mishra D, Midha D, Gupta N, Arora N, Gupta P, Gupta P, Singh V, Jain D
Abstract
The presence of activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene in adenocarcinomas of lung confers sensitivity to tyrosine kinase inhibitor therapy. The prevalence of EGFR mutations varies among different ethnicities and demographic profile. This multi-institutional data was compiled to determine the EGFR mutation status in Indians patients with lung adenocarcinoma. Cohorts represented by 4 tertiary care hospitals participated in data discussion at a national conference entitled as 'Lung Cancer Management in Indian Context'. The clinicopathologic data and EGFR mutation rate in the patients of lung adenocarcinoma screened in these cohorts were collected and analyzed. The sample types included both surgical and cytological specimens. A variety of methods were used including immunohistochemistry, polymerase chain reaction, Sanger sequencing and next generation sequencing. A total of 3436 cases of treatment naïve lung adenocarcinoma were tested for EGFR mutations. The overall frequency of EGFR mutations observed was 30.03%. The most common baseline mutation detected was exon 19 deletion followed by L858R point mutation in exon 21. Dual mutations were observed in 6.5% of cases and were predominantly combinations of exon 19 deletion and T790M point mutation in exon 20. Incidence of EGFR mutations was higher among females and non-smokers diagnosed with lung adenocarcinomas. The most common histology in EGFR mutant cases was acinar predominant adenocarcinomas. With nearly one-third of Indian patients with lung adenocarcinoma harboring EGFR mutations, routine testing for these mutations is important to get the benefit of targeted therapy.
PMID: 32169258 [PubMed - as supplied by publisher]
-
Prostatic Ductal Adenocarcinoma Controlled for Cancer Grade and Tumor Volume Does Not Have an Independent Effect on Adverse Radical Prostatectomy Outcomes Compared to Usual Acinar Prostatic Adenocarcinoma.
Fetched: March 14th, 2020, 5:00am GMT
Related Articles Prostatic Ductal Adenocarcinoma Controlled for Cancer Grade and Tumor Volume Does Not Have an Independent Effect on Adverse Radical Prostatectomy Outcomes Compared to Usual Acinar Prostatic Adenocarcinoma.
Urology. 2020 Mar;137:108-114
Authors: Iakymenko OA, Lugo I, Kwon D, Zhao W, Hayee A, Punnen S, Parekh DJ, Pollack A, Ritch CR, Gonzalgo ML, Stoyanova R, Jorda M, Kryvenko ON
Abstract
OBJECTIVE: To study if prostatic ductal adenocarcinoma (PDA) controlled by Grade Group (GG), PSA, and tumor volume (TV) is an independent predictor of adverse radical prostatectomy (RP) outcomes.
MATERIALS: One-hundred and twenty-eight PDA and 1141 acinar continuous RPs were studied. Each tumor nodule (TN) was individually graded, staged, and its TV measured. Univariate analysis (UVA) identified features associated with lymph node metastasis (LN+), extraprostatic extension (EPE), positive surgical margins (SM+), and seminal vesicle invasion (SV+). We then assessed PDA effect on RP outcomes in a multivariate analysis (MVA).
RESULTS: In 127 cases PDA was present in 1 TN and no TN was pure PDA. One-hundred and twenty-three cases had PDA in TNs with highest grade, stage, and TV. Patients with PDA were older (65 vs 63 years, P < 0.001), had higher GG (P < 0.001), and LN+ (6.3% vs 2.7%, P = 0.049). Controlling these variables by GG eliminated statistical significance. Overall, there were 3249 separate TNs (129 PDA and 3120 acinar). In UVA, PDA predicted EPE (92/124 vs 517/3045), SV+ (28/1129 vs 116/3,120), and SM+ (51/129 vs 296/3120), all P < 0.001. In MVA, PDA lost its effect on EPE (OR = 0.88, P = 0.64), SM+ (OR = 0.86, P = 0.5), and SV+ (OR = 0.99, P = 0.98).
CONCLUSION: Controlled for grade and TV, PDA was not an independent predictor of adverse RP outcomes, but former 2 were. Hence, higher GG and TV associated with PDA TNs may be predictive of adverse RP outcomes rather than PDA by itself. These conclusions may be used in preoperative risk stratification and definitive therapy planning when PDA is identified on needle biopsy.
PMID: 31711982 [PubMed - indexed for MEDLINE]
-
Computed tomography features of acinar cell carcinoma of the pancreas.
Fetched: March 10th, 2020, 5:00am GMT
Related Articles Computed tomography features of acinar cell carcinoma of the pancreas.
Diagn Interv Imaging. 2020 Mar 04;:
Authors: Barat M, Dohan A, Gaujoux S, Hoeffel C, Jornet D, Oudjit A, Coriat R, Barret M, Terris B, Soyer P
Abstract
PURPOSE: To report the computed tomography (CT) features of pancreatic acinar cell carcinoma (ACC) and identify CT features that may help discriminate between pancreatic ACC and pancreatic ductal adenocarcinoma (PDA).
MATERIALS AND METHODS: The CT examinations of 20 patients (13 men, 7 women; mean age, 66.5±10.7 [SD] years; range: 51-88 years) with 20 histopathologically proven pancreatic ACC were reviewed. CT images were analyzed qualitatively and quantitatively and compared to those obtained in 20 patients with PDA. Comparisons were performed using univariate analysis with a conditional logistic regression model.
RESULTS: Pancreatic ACC presented as an enhancing (20/20; 100%), oval (15/20; 75%), well-delineated (14/20; 70%) and purely solid (13/20; 65%) pancreatic mass with a mean diameter of 52.6±28.0 (SD) mm (range: 24-120mm) in association with visible lymph nodes (14/20; 70%). At univariate analysis, well-defined margins (Odds ratio [OR], 7.00; P=0.005), nondilated bile ducts (OR, 9.00; P=0.007), visible lymph nodes (OR, 4.33; P=0.028) and adjacent organ involvement (OR, 5.67; P=0.02) were the most discriminating CT features to differentiate pancreatic ACC from PDA. When present, lymph nodes were larger in patients with pancreatic ACC (14±4.8 [SD]; range: 7-25mm) than in those with PDA (8.8±4.1 [SD]; range: 5-15mm) (P=0.039).
CONCLUSION: On CT, pancreatic ACC presents as an enhancing, predominantly oval and purely solid pancreatic mass that most frequently present with no bile duct dilatation, no visible lymph nodes, no adjacent organ involvement and larger visible lymph nodes compared to PDA.
PMID: 32146131 [PubMed - as supplied by publisher]
-
Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours.
Fetched: March 2nd, 2020, 5:00am GMT
Related Articles Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours.
Pathology. 2020 Feb 25;:
Authors: Kim JY, Brosnan-Cashman JA, Kim J, An S, Lee KB, Kim H, Park DY, Jang KT, Oh YH, Hruban RH, Heaphy CM, Hong SM
Abstract
Acinar cell carcinomas (ACCs) and mixed acinar-neuroendocrine carcinomas (MAcNECs) of the pancreas are extremely rare carcinomas with a significant component with acinar differentiation. To date, the clinicopathological behaviours of these neoplasms remain unclear. In this study, we evaluated the histopathological and molecular characteristics of 20 ACCs and 13 MAcNECs and compared them to a cohort of 269 well-differentiated pancreatic neuroendocrine tumours (PanNETs). Compared to PanNETs, both ACCs and MAcNECs had an advanced pT classification (p<0.001), as well as more prevalent lymphovascular and perineural invasion (p=0.002) and lymph node and distant metastases (p<0.001). Patients with MAcNECs had worse overall (p<0.001) and recurrence-free survival (p<0.001) than those with PanNETs, but no significant difference with those with ACCs. Subgroup analyses revealed that patients with ACCs and MAcNECs had significantly worse recurrence-free survival than those with grade 1 PanNET (p<0.001), and patients with MAcNECs also had worse overall survival than those with grade 1 and 2 PanNETs (p<0.001, and p=0.001). ACCs presented more commonly with intraductal growth (p=0.014) than MAcNECs, while MAcNECs more often had lymph node metastasis (p=0.012) than ACCs. The telomere maintenance mechanism Alternative Lengthening of Telomeres (ALT) was assessed by telomere-specific FISH, and ALT was detected in 1 of 20 ACCs and in three of the 13 MAcNECs. Patients with MAcNECs and ACCs had worse survival and more aggressive behaviour than those with grade 1 PanNETs; thus, the clinicopathological behaviour of MAcNECs resembles ACCs rather than PanNETs. Combined neuroendocrine and acinar cell immunohistochemical markers are helpful for differentiating these different tumour types.
PMID: 32111396 [PubMed - as supplied by publisher]
-
MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes.
Fetched: March 1st, 2020, 5:00am GMT
Related Articles MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes.
Ann Surg Oncol. 2020 Feb 27;:
Authors: Fraune C, Burandt E, Simon R, Hube-Magg C, Makrypidi-Fraune G, Kluth M, Büscheck F, Höflmayer D, Blessin NC, Mandelkow T, Li W, Perez D, Izbicki JR, Wilczak W, Sauter G, Schrader J, Neipp M, Mofid H, Daniels T, Isbert C, Clauditz TS, Steurer S
Abstract
BACKGROUND: Microsatellite instability (MSI) has emerged as a predictive biomarker for immune checkpoint inhibitor therapy. Cancer heterogeneity represents a potential obstacle for the analysis of predicitive biomarkers. MSI has been reported in pancreatic cancer, but data on the possible extent of intratumoral heterogeneity are lacking.
METHODS: To study MSI heterogeneity in pancreatic cancer, a tissue microarray (TMA) comprising 597 tumors was screened by immunohistochemistry with antibodies for the mismatch repair (MMR) proteins MLH1, PMS2, MSH2, and MSH6.
RESULTS: In six suspicious cases, large section immunohistochemistry and microsatellite analysis (Bethesda panel) resulted in the identification of 4 (0.8%) validated MSI cases out of 480 interpretable pancreatic ductal adenocarcinomas. MSI was absent in 55 adenocarcinomas of the ampulla of Vater and 7 acinar cell carcinomas. MMR deficiency always involved MSH6 loss, in three cases with additional loss of MSH2 expression. Three cancers were MSI-high and one case with isolated MSH6 loss was MSS in PCR analysis. The analysis of 44 cancer-containing tumor blocks revealed that the loss of MMR protein expression was always homogeneous in affected tumors. Automated digital image analysis of CD8 immunostaining demonstrated markedly higher CD8 + tumor infiltrating lymphocytes in tumors with (mean = 685, median = 626) than without (mean = 227; median = 124) MMR deficiency (p < 0.0001), suggesting a role of MSI for immune response.
CONCLUSIONS: Our data suggest that MSI occurs early in a small subset of ductal adenocarcinomas of the pancreas and that immunohistochemical MMR analysis on limited biopsy or cytology material may be sufficient to estimate MMR status of the entire cancer mass.
PMID: 32108923 [PubMed - as supplied by publisher]
-
Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland.
Fetched: February 27th, 2020, 5:00am GMT
Related Articles Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland.
Virchows Arch. 2020 Feb;476(2):295-305
Authors: Bell D, Ferrarotto R, Liang L, Goepfert RP, Li J, Ning J, Broaddus R, Weber RS, El-Naggar AK
Abstract
Secretory carcinoma of the salivary gland is a newly recognized entity that morphologically resembles breast secretory carcinoma and has a characteristic t(12;15)(p13;q25) ETV6-NTRK3 translocation. Fluorescence in situ hybridization (FISH) or reverse transcription polymerase chain reaction (RT-PCR) analyses can detect the ETV6-NTRK3 fusion; however, both tests are expensive and not widely available. In this study, we aimed to determine whether pan-Trk immunohistochemistry (IHC) could detect ETV6-NTRK3 fusions as reliably as RT-PCR and FISH. We performed pan-Trk IHC in 70 salivary gland cancer samples, including secretory carcinomas, acinic cell carcinomas, and hybrid carcinomas. Nineteen tumors exhibited positive pan-Trk staining, including 16 secretory carcinomas, 2 hybrid carcinomas with a secretory carcinoma component, and 1 acinic cell carcinoma. Pan-Trk IHC staining was localized in the nucleus in 16 (84.2%) cases and in the cytoplasm and/or membrane in 3 (15.8%) cases. RT-PCR analysis for the ETV6-NTRK3 transcript was conducted in 45 samples; the fusion transcript was present in 11 of 12 secretory carcinomas and absent in 32 acinic cell carcinomas and 1 mucoepidermoid carcinoma. Pan-Trk IHC was positive in 10 of 11 salivary tumors that were positive for ETV6-NTRK3 by RT-PCR and negative in all 34 tumors that were negative for the fusion by RT-PCR. Therefore, in comparison with RT-PCR, pan-Trk IHC had a sensitivity of 90.9% and specificity of 100%. In conclusion, our data showed that pan-Trk IHC is a reasonable screening test for diagnosing secretory carcinoma of the salivary gland.
PMID: 31423558 [PubMed - indexed for MEDLINE]
-
Corrigendum to "Pancreatic acinar cell carcinoma-literature review and case report of a 56-year-old man presenting with abdominal pain" [Radiol Case Rep 15 (2020) 39-43].
Fetched: February 21st, 2020, 5:00am GMT
Related Articles Corrigendum to "Pancreatic acinar cell carcinoma-literature review and case report of a 56-year-old man presenting with abdominal pain" [Radiol Case Rep 15 (2020) 39-43].
Radiol Case Rep. 2020 Mar;15(3):306-307
Authors: Fontenot J, Spieler B, Hudson C, Boulmay B
Abstract
[This corrects the article DOI: 10.1016/j.radcr.2019.10.009.].
PMID: 32071654 [PubMed - in process]
-
MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages.
Fetched: February 16th, 2020, 5:00am GMT
Related Articles MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages.
Oncogene. 2019 07;38(28):5599-5611
Authors: Babicky ML, Harper MM, Chakedis J, Cazes A, Mose ES, Jaquish DV, French RP, Childers B, Alakus H, Schmid MC, Foubert P, Miyamoto J, Holman PJ, Walterscheid ZJ, Tang CM, Varki N, Sicklick JK, Messer K, Varner JA, Waltz SE, Lowy AM
Abstract
The MST1R (RON) kinase is overexpressed in >80% of human pancreatic cancers, but its role in pancreatic carcinogenesis is unknown. In this study, we examined the relevance of Mst1r kinase to Kras driven pancreatic carcinogenesis using genetically engineered mouse models. In the setting of mutant Kras, Mst1r overexpression increased acinar-ductal metaplasia (ADM), accelerated the progression of pancreatic intraepithelial neoplasia (PanIN), and resulted in the accumulation of (mannose receptor C type 1) MRC1+, (arginase 1) Arg+ macrophages in the tumor microenvironment. Conversely, absence of a functional Mst1r kinase slowed PanIN initiation, resulted in smaller tumors, prolonged survival and a reduced tumor-associated macrophage content. Mst1r expression was associated with increased production of its ligand Mst1, and in orthotopic models, suppression of Mst1 expression resulted in reduced tumor size, changes in macrophage polarization and enhanced T cell infiltration. This study demonstrates the functional significance of Mst1r during pancreatic cancer initiation and progression. Further, it provides proof of concept that targeting Mst1r can modulate pancreatic cancer growth and the microenvironment. This study provides further rationale for targeting Mst1r as a therapeutic strategy.
PMID: 30967626 [PubMed - indexed for MEDLINE]
-
Unusual synchronous double primary treatment-naïve lung adenocarcinoma harboring T790M and L858R mutations in early-stage lung cancer.
Fetched: February 9th, 2020, 5:00am GMT
Related Articles Unusual synchronous double primary treatment-naïve lung adenocarcinoma harboring T790M and L858R mutations in early-stage lung cancer.
World J Surg Oncol. 2019 Aug 19;17(1):148
Authors: Weng CF, Chen PJ, Tseng AH, Huang SH, Lee HH
Abstract
BACKGROUND: Concurrent mutations of synchronous multiple primary non-small cell lung cancer (SMPNSCLC) is rare, and only a few cases have been reported. Herein, we present a case of early-stage SMPNSCLC with T790M and L858R mutations.
CASE PRESENTATION: A 68-year-old male patient presented to the Thoracic Surgery Department due to a tumor in the right lower lung. The tumor was detected more than 5 years previously during a health examination; however, the patient ignored the problem because the clinician at that time stated that the lesion was highly likely to be benign. Chest computed topography (CT) was ordered and the images showed a well-defined tumor in the right lower lung and a faint nodular lesion over the left lower lung field. A CT-guided biopsy results showed the presence of atypical cells and positive staining of TTF-1 and CK7. Surgical intervention was performed. The right- and left-sided tumors disclosed micropapillary predominant adenocarcinoma and acinar-predominant adenocarcinoma, respectively. Both tumors were positive for TTF-1 but negative for ALK and p40. Real-time PCR analysis showed that the right-sided tumor had an epidermal growth factor receptor (EGFR) mutation presenting as point mutation T790M in exon 20, while the left-sided tumor had a point mutation L858R in exon 21 of EGFR.
CONCLUSIONS: Our patient's case suggests that tumors resembling a benign pattern with central calcification may be misdiagnosed. Thus, early screening for lung cancer is important, and intensive efforts to make a diagnosis through surgical resection or biopsies to allow for tailored optimal treatment may be preferential for the best patient outcomes.
PMID: 31426797 [PubMed - indexed for MEDLINE]
-
Insulinoma-associated protein 1 (INSM1) is a robust marker for identifying and grading pancreatic neuroendocrine tumors.
Fetched: January 26th, 2020, 5:00am GMT
Related Articles Insulinoma-associated protein 1 (INSM1) is a robust marker for identifying and grading pancreatic neuroendocrine tumors.
Cancer Cytopathol. 2020 Jan 24;:
Authors: Kim D, Viswanathan K, Goyal A, Rao R
Abstract
BACKGROUND: Pancreatic neuroendocrine tumor (PNET) is a diagnostic challenge with limited samples in not only identification but grading. Prior studies have shown insulinoma-associated protein 1 (INSM1) to be a robust marker in identifying PNETs from other solid pancreatic tumors on resection specimens. In this study, we investigated the utility of INSM1 not only for identifying PNETs but also for grading in cell blocks (CBs) and surgical resections (SRs).
METHODS: A search for PNET cases between 2000 and 2019 identified 55 samples (26 CBs and 29 SRs) that were further separated into high (2 CBs, 3 SRs), intermediate (4 CBs, 7 SRs), and low (20 CBs, 19 SRs) grades based on their final pathology report and Ki-67 level. Immunohistochemical (IHC) staining for INSM1 (C-8, Santa Cruz Biotechnology [1:100]) was performed and quantified using an H score of 0 to 300. Non-PNET solid pancreatic tumors were compared and included acinar cell carcinoma, solid pseudopapillary neoplasm, and ductal adenocarcinoma.
RESULTS: All 55 cases of PNET demonstrated nuclear INSM1 staining. The average H scores for INSM1 staining of PNET were 254 and 252 in CB and SR, respectively. The H scores decreased with increasing tumor grade, with low-grade (G1), intermediate-grade (G2), and high-grade (G3) tumors showing average INSM1 H scores of 229 and 253, 266 and 253, and 30 and 33 in both CB and SR, respectively.
CONCLUSION: IHC with INSM1 plays a role in identifying and potentially grading PNETs.
PMID: 31977134 [PubMed - as supplied by publisher]
Google - Acinic Cell Carcinoma
-
Pet rescuer with chronic illness wins award for rehoming hundreds of kittens - Mirror Online
Posted: March 7th, 2020, 4:17pm GMT
-
Tiffany Cohen Lalonde's Son Daniel Diagnosed With Cancer: Fighting Fund Launched - Swimming World Magazine
Posted: February 22nd, 2020, 4:47pm GMT
Tiffany Cohen Lalonde's Son Daniel Diagnosed With Cancer: Fighting Fund Launched Swimming World Magazine -
Salivary gland cancer: Symptoms, causes, diagnosis, and treatment - Medical News Today
Posted: September 30th, 2019, 5:00am GMT
Salivary gland cancer: Symptoms, causes, diagnosis, and treatment Medical News Today -
Dunstable author hopes Sunny Days will inspire others - Dunstable Today
Posted: February 26th, 2019, 6:00am GMT
Dunstable author hopes Sunny Days will inspire others Dunstable Today